Association of British Clinical Diabetologists

Welcome to ABCD on N3

 
Home Live ABCD audits of new therapies and devices All ABCD nationwide audits Future audits of new therapies ABCD worldwide audits
     

Above - centres contributing to the ABCD nationwide exenatide (left) and liraglutide (right) audits – click to enlarge

 

Above: In real clinic practice in the UK, patients treated with exenatide or liraglutide had far worse glycaemic control and were much heavier than patients treated in clinical trials  – click to enlarge

 

Above: Though the combination of exenatide and insulin was not licensed at the time of the ABCD nationwide exenatide audit, many contributors to the audit found benefits from the combination  – click to enlarge

The Association of British Clinical Diabetologists on N3

The Association of British Clinical Diabetologists (ABCD) is delighted to have achieved a presence on N3. This page is not itself on N3, as we wish the information to be universally available, but these pages form ABCD's portal into N3.

What is N3 and why a presence on it for ABCD?
N3 is the national broadband network for the National Health Service (NHS), connecting all NHS locations, in particular linking acute hospitals and GP surgeries. The important thing from ABCD’s point of view is that it is the official secure place for storing patient data of NHS patients and therefore the most appropriate and secure place for holding our nationwide audit data in the future. Centres joining the national audit effort will be able to access their own patient data on their local NHS computers as they do with their other local clinical systems. They will be able to access and audit their own local data in order to learn from the local experience.

Why ABCD nationwide audits
At the same time the data, in anonymised form, will be joined to the nationwide audit where, by being combined with similar data from all over the UK,
the rate at which we can learn about new medications in real clinical practice is increased - through the force of numbers. For example it can be seen from the slide, lower left, than we learned from the nationwide exenatide and liraglutide audits, that in real clinic practice patients treated with these medications in the UK had far worse glycaemic control and were much heavier than patients treated in clinical trials - thus reducing the extent to which information from the clinical trials can be extrapolated to real clinical life. ABCD hopes, through its audits, to gain insights into both safety and efficacy of new medications. ABCD hopes that the data collected will inform future practice and guidelines. More information on previous ABCD audits....

The first ABCD national audit to take place on N3 is the nationwide exenatide qw audit. Further information on the ABCD nationwide audit programme can be obtained by contacting us at abcd.audits@diabetologists.org.uk.

   Main ABCD homepage

ABCD canagliflozin audit

ABCD dapagliflozin audit

ABCD empagliflozin audit

ABCD FreeStyle Libre audit

 ABCD exenatide QW audit

ABCD IDegLira audit

ABCD degludec audit

ABCD liraglutide audit

ABCD exenatide audit

ABCD worldwide audits

Endobarrier worldwide registry

Contact us

     

Working to support high quality diabetes care in the UK